Successful TQT Studies
TQT Studies are an indispensible part of the development of new chemical entities (NCE). These studies are significant and their outcome has major impact on a drug development program. Though, these studies are rather novel and there may still be a level of doubt when assigning the studies
3 causes’ of this uncertainty is outlined below:
• Best practice for the conduct of TQT studies is still emerging
• Overall, these studies are generally expensive to conduct
• ECG central core laboratories do not have any incentive to develop efficient methods for assessing NCEs
undertaking the conduct, design, analysis and concept
A positive signal in a TQT study does not mean that a NCE will cause Torsades de Pointes (TdP) with the associated risk of sudden death.
A positive signal has however a major impact on the development of a NCE. For this reason, the early conduct of a TQT study is desirable but the cost may be prohibitive given the high attrition rate in early phase studies.
Richmond Pharmacology is Europe’s leading Medical Research Provider specialising in TQT studies, Clinical Data Management and Clinical Research. With a Core ECG Lab and experienced medical professionals Richmond Pharmacology conducts Clinical Trials for the purpose of new Drug Development
Essentials
TQT studies could be conducted at a much earlier stage of development and in any case more
frequently, if a there is a significant reduction in cost, based on 3 key elements can be
achieved.
These are
• Design
• Conduct
• Analysis
